Natural looking

Dysport provides temporary improvement in the appearance of moderate to severe frown lines that are caused by the activity of the procerus and corrugator muscles in patients.1 Dysport helps them look consistently natural—not frozen—because it allows the untreated facial muscles to work normally, which in turn helps patients freely show facial expressions in untreated areas.

Satisfied patient with her natural-looking results from Dysport treatment
    Actual patient. Individual results may vary.

Fast acting

Dysport acts quickly for patients. Some users* saw results within 24 hours,2-4† while more than half of users saw improvement in as little as 2-3 days after treatment with 50 units of Dysport versus placebo.2-4†

Graph showing Dysport patient results over time from Pivotal study
  • Users=clinical trial subjects.
  • Based on subject self-assessment. The onset of response at day 1 was 15% (16/105) in GL-1 and 33% (65/200) in GL-3. In the DREAM study, the onset of response at day 1 was 33% (66/200). The median time to onset of response was 3 days in GL-1 (55/105; 52%) and GL-2 (36/71; 51%), and 2 days in GL-3 (110/200; 55%).
    The GL-1 study was a 6-month, single-dose, double-blind, multicenter, randomized, placebo-controlled study (N=158) to assess the safety and efficacy of 50 units of Dysport vs placebo in subjects with moderate to severe glabellar lines at maximum frown.2 55% (58/105) of Dysport subjects vs 0/53 patients treated with placebo met the primary endpoint.

Long lasting

Dysport delivered proven efficacy at every time point for up to 5 months.2,3,5* Moreover, the experience proved beneficial for users, with 98% of users† wanting to receive another Dysport treatment following 2 treatments.6

Graph with study results on long-lasting 5-month clinical effect
  • GL-1 and GL-3 evaluated subjects once a month for at least 5 months following treatment. Based on a ≥1-grade GLSS improvement from baseline utilizing data from two double-blinded, randomized, placebo-controlled pivotal studies (GL-1, GL-3) in a post-hoc analysis. On average, efficacy was 97% at month 1, 90% at month 2, 81% at month 3, 63% at month 4, and 40% at month 5.
  • Users=clinical trial subjects.

A well-established safety profile

Dysport has long-term safety results studied over three years7

  • Well tolerated
  • Low ptosis rate
  • No cumulative effect of repeated treatments8-10
  • Decreased incidence of treatment/injection-related reactions over repeated cycles

Chart showing Dysport safety information
    Most common side effects: As with any botulinum toxin type A treatment, the most common side effects are nose and throat irritation, headache, injection site pain, injection site skin reaction, upper respiratory tract infection, eyelid swelling, eyelid drooping, sinus inflammation and nausea. See below for complete Important Safety Information.

Definitely Dysport means real results

  • 98%
    of users* wanted to receive treatment again after 2 treatments.6*†
  • 97%
    of toxin-naive users were satisfied after receiving 2 treatments, 6 months apart.6*†
  • 97%
    of users felt their results looked natural.11*‡
  • 95%
    of users felt confident, attractive, and happy after treatment.6*†§
98%
of users* wanted to receive treatment again after 2 treatments.6*†
97%
of toxin-naive users were satisfied after receiving 2 treatments, 6 months apart.6*†
97%
of users felt their results looked natural.11*‡
95%
of users felt confident, attractive, and happy after treatment.6*†§

    *Users=clinical trial subjects.
    †Subject-reported at 12 months (N=120) after two treatments
    six months apart in a phase IV, multicenter, prospective study.
    ‡3 out of 10 FACE-Q questions about psychological function are shown.
    § Subject-reported (N=559) at 3 weeks in a prospective, non-interventional, observational, multicenter study in response to a questionnaire. Subjects were eligible if the investigator had already decided to prescribe Dysport according to labeling.

Build your business with ASPIRE Galderma Practice Rewards

Empower business growth. Strengthen patient relationships. 
ASPIRE Galderma Practice Rewards is a program designed to strengthen the relationship you build with your aesthetics patients. As your connections grow, so does your practice,
and we’re here to support both with valuable insights, product offers, and practice tools.

Join now Sign in

GAIN Training

It’s the simple and effective way to get started with Dysport. You can be confident in this efficacious, safe, and distinctively premium brand that can help uplift your patients to feel more confident. Once partnered, you have access to our top-tier products and support in areas like data, training, and safety, giving you the tools to help grow your business.
Enroll in my GAIN training
Apple app store logo Google play app store logo
Download the Galderma GAIN app to stay connected

Easy to administer and reconstitute

Learn how to dose Dysport for moderate to severe glabellar lines.

We invite healthcare professionals to download this Dysport Reconstitution Guide or watch the video below to learn the proper application and administration methods, dosage amounts, and reconstitution process for Dysport treatment.

Download Reconstitution Guide

Contact Galderma

Please contact the Galderma Special Services team, available Monday to Friday, from 8:00 am to 5:00 pm CT.

More ways to contact Galderma

You can reach our Galderma US Aesthetics Support Team by calling 1-800-221-1749 or emailing inside.sales@galderma.com.

For medical inquiries, including reporting adverse medical reactions to a Galderma product, please call 1-866-735-4137.

Bringing Dysport to Your Practice

If you would like to offer our treatment through your practice, please contact the Galderma Special Services team, available Monday to Friday, from 8:00 am to 5:00 pm CT at 1-800-221-1749 or emailing inside.sales@galderma.com.

More ways to contact Galderma

To Order Dysport

If you would like to order Dysport for your patients or reorder stock for your practice, please contact the Galderma Special Services team by phone Monday to Friday, from 8:00 AM to 5:00 PM CT at 1-800-221-1749 or by email at inside.sales@galderma.com.

More ways to contact Galderma

Find a Specialist

The “Find a specialist” feature on DysportUSA.com makes it easy for patients to contact you regarding aesthetic treatment. To remain on the Dysport "Find a specialist" feature, please place an order for Dysport every 6 months at minimum.

Identifying Authentic Dysport

The best way to protect your patients from counterfeit Dysport is to verify that you’re ordering authentic Dysport from an authorized distributor. Be sure to check the packaging of your product to make sure it’s authentic.



There are more anti-counterfeiting measures on the packaging that aren’t listed here. Ask your distributor for more information.

image
References
  1. Dysport Prescribing Information. Galderma Laboratories, L.P. Dallas, TX. 2023.
  2. Data on file. GL-Y-97-52120-719 (GL-1) Clinical Study Report. Fort Worth, TX: Galderma Laboratories, L.P., 2007.
  3. Data on file. GL-Y-97-52120-718 (GL-3) Clinical Study Report. Fort Worth, TX: Galderma Laboratories, L.P., 2007.
  4. Data on file. GL-Y-97-52120-085 (GL-2) Clinical Study Report. Fort Worth, TX: Galderma Laboratories, L.P., 2007.
  5. Data on file. MA-35497. Post Hoc Analysis. Fort Worth, TX: Galderma Laboratories, L.P., 2017.
  6. Data on file. 43USD1802 Clinical Study Report. Fort Worth, TX: Galderma Laboratories, L.P., 2020.
  7. Schlessinger J, et al. Long-term safety of abobotulinumtoxinA for the treatment of glabellar lines: results from a 36-month, multicenter, open-label extension study. Dermatol Surg. 2014;40(2):176-183.
  8. Rubin MG, et al. The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment. J Drugs Dermatol. 2009;8(5):439-444.
  9. Moy R, et al. Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines. Arch Facial Plast Surg. 2009;11(2):77-83.
  10. Cohen JL, et al. An analysis of the long-term safety data of repeat administrations of botulinum neurotoxin type A-ABO for the treatment of glabellar lines. Aesthet Surg J. 2009;29(6 Suppl):S43-49.
  11. Molina B, et al. Patient satisfaction after 3 weeks in the treatment of glabellar lines with Botulinum toxin type A. J Eur Acad Dermatol Venereol. 2015;29:1382-1388.
Please see full Important Safety Information
for Dysport, for frown lines between the brows,including Distant Spread of Toxin Effect Boxed Warning at bottom of page.
Please see full Important Safety Information

for Dysport, for frown lines between the brows, including Distant Spread of Toxin Effect Boxed Warning at bottom of page.

Important Safety Information

Dysport® (abobotulinumtoxinA) is a prescription injection for temporary improvement in the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults less than 65 years of age.

Important Safety Information

What is the most important information you should know about Dysport? Spread of Toxin Effects: In some cases, the effects of Dysport and all botulinum toxin products may affect areas of the body away from the injection site. Symptoms can happen hours to weeks after injection and may include swallowing and breathing problems, loss of strength and muscle weakness all over the body, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, or loss of bladder control. Swallowing and breathing problems can be life threatening and there have been reports of death. You are at the highest risk if these problems are pre-existing before injection.

These effects could make it unsafe for you to drive a car, operate machinery, or do other dangerous activities.

Do not have Dysport treatment if you: are allergic to Dysport or any of its ingredients (see the end of the Medication Guide for a list of ingredients), are allergic to cow's milk protein, had an allergic reaction to any other botulinum toxin product, such as Myobloc®, Botox®, or Xeomin®, have a skin infection at the planned injection site, under 18 years of age, or are pregnant or breastfeeding.

The dose of Dysport is not the same as the dose of any other botulinum toxin product and cannot be compared to the dose of any other product you may have used.

Tell your doctor about any swallowing or breathing difficulties and all your muscle or nerve conditions such as amyotrophic lateral sclerosis [ALS or Lou Gehrig's disease], myasthenia gravis, or Lambert-Eaton syndrome, which may increase the risk of serious side effects including difficulty swallowing and difficulty breathing. Serious allergic reactions have occurred with the use of Dysport. Dry eye has also been reported.

Tell your doctor about all of your medical conditions, including if you have surgical changes to your face, very weak muscles in the treatment area, any abnormal facial change, injection site inflammation, droopy eyelids or sagging eyelid folds, deep facial scars, thick oily skin, wrinkles that can't be smoothed by spreading them apart, or if you are pregnant or breastfeeding or planning to become pregnant or breastfeed.

Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins and herbal and other natural products. Using Dysport with certain other medicines may cause serious side effects. Do not start any new medicines while taking Dysport without talking to your doctor first.

Especially tell your doctor if you: have received any other botulinum toxin product, such as Myobloc® (rimabotulinumtoxinB), Botox® (onabotulinumtoxinA), or Xeomin® (incobotulinumtoxinA), in the last four months or any in the past (be sure your doctor knows exactly which product you received), have recently received an antibiotic by injection, take muscle relaxants, take an allergy or cold medicine, or take a sleep medicine.

Common Side Effects

The most common side effects are nose and throat irritation, headache, injection site pain, injection site skin reaction, upper respiratory tract infection, eyelid swelling, eyelid drooping, sinus inflammation, and nausea.

Ask your doctor if Dysport is right for you.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see Dysport Full Prescribing Information including Medication Guide.

US-DYS-2300210